AFMA S.A. (CBSE:AFM)

Ligand Pharmaceuticals Cash Flow Statement

Financials in millions MAD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Jun 30, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Net Income	-	60	59.32	57.85	42.56	50.14
Depreciation & Amortization	-	15.39	13.73	11.77	10.95	9.61
Loss (Gain) From Sale of Assets	-	0.41	-0.31	0.61	-0.2	-
Other Operating Activities	-	3.26	4.04	4.35	-0.57	0.02
Change in Other Net Operating Assets	-	2.56	-35.27	-16.89	46.49	46.09
Operating Cash Flow	-	81.61	41.5	57.7	99.23	105.85
Operating Cash Flow Growth	-	96.63%	-28.07%	-41.85%	-6.26%	124.50%
Capital Expenditures	-	-15.21	-13.47	-7.16	-3.5	-5.64
Sale of Property, Plant & Equipment	-	-	0.09	0.39	-	-
Cash Acquisitions	-	-0.4	-5.3	-9.06	-10.5	-1.05
Investment in Securities	-	-0.01	-0.15	0.92	1.36	-
Other Investing Activities	-	7	5.31	4.26	2.76	3.6
Investing Cash Flow	-	-8.62	-13.52	-10.65	-9.89	-3.09
Long-Term Debt Issued	-	-	17.4	-	15	-
Long-Term Debt Repaid	-	-13.74	-13.43	-14.96	-11.69	-8.72
Net Debt Issued (Repaid)	-	-13.74	3.97	-14.96	3.31	-8.72
Issuance of Common Stock	-	0.4	4.05	-	0.35	-
Common Dividends Paid	-	-63	-60.84	-51.71	-56.5	-60.6
Financing Cash Flow	-	-76.34	-52.82	-66.67	-52.84	-69.32
Foreign Exchange Rate Adjustments	-	0.02	0.06	0.05	-	-
Miscellaneous Cash Flow Adjustments	-	-0	0	-	-	-
Net Cash Flow	-	-3.34	-24.78	-19.57	36.5	33.44
Free Cash Flow	-	66.39	28.03	50.54	95.73	100.21
Free Cash Flow Growth	-	136.86%	-44.54%	-47.21%	-4.47%	117.84%
Free Cash Flow Margin	-	25.66%	11.50%	22.78%	47.01%	51.68%
Free Cash Flow Per Share	-	66.40	28.03	50.53	95.73	100.21
Cash Income Tax Paid	-	29.24	27.6	24.68	23.53	22.39
Levered Free Cash Flow	-	63.55	22.93	43.63	105.41	92
Unlevered Free Cash Flow	-	67.81	26.57	47.2	108.58	95.51
Change in Net Working Capital	-13.43	-1.51	36.03	15.76	-46.52	-41.23

Updated Sep 30, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.